CYP46A1 T/C polymorphism associated with the APOEε4 allele increases the risk of Alzheimer’s disease

被引:0
作者
Ling Li
Zegang Yin
Juan Liu
Gongbo Li
Yanjiang Wang
Jiachuan Yan
Huadong Zhou
机构
[1] Daping Hospital,Department of Neurology and Center for Clinical Neuroscience
[2] Third Military Medical University,undefined
来源
Journal of Neurology | 2013年 / 260卷
关键词
Cholesterol 24S-hydroxylase gene (; ); Apolipoprotein E (; ); Alzheimer’s disease (AD); Meta-analysis; Polymorphism;
D O I
暂无
中图分类号
学科分类号
摘要
Studies of the relationship between Alzheimer’s disease (AD) and single nucleotide polymorphism (SNP) T/C in intron 2 of the cholesterol-24S-hydroxylase gene (CYP46A1) have reported inconsistent results. To confirm the association between the CYP46A1 T/C polymorphism and AD risk, a meta-analysis containing 4,875 AD cases and 4,874 controls from 21 case–control studies was performed. There were 16 studies involving Europeans, four studies with Asians and one study with Africans. The combined results of overall analysis showed that the CYP46A1 T/C polymorphism increased the risk of AD significantly in recessive model [CC versus CT + TT, odds ratio (OR) = 1.20, 95 % confidence interval (CI) = 1.04–1.38, p = 0.01]. On subgroup analysis by ethnicity, similarly significant differences in recessive model were also found in Europeans. Another analysis of the synergistic effect of the CYP46A1 T/C polymorphism and the ε4 allele of the apolipoprotein E gene (APOE ε4) was performed in eight studies with available stratified information. The results revealed that the presence of APOE ε4 allele could strengthen the effect of CC genotype on AD risk, and the reverse was also true. In conclusion, our meta-analysis has successfully proved that CC genotype of the CYP46A1 T/C polymorphism could increase the risk of AD, and this effect would be weakened in APOE ε4 non-carriers and strengthened in APOE ε4 carriers.
引用
收藏
页码:1701 / 1708
页数:7
相关论文
共 124 条
[21]  
Grimaldi M(2006)Association studies of cholesterol metabolism genes (CH25H, ABCA1 and CH24H) in Alzheimer’s disease Neurosci Lett 391 142-146
[22]  
Ramunno A(2006)Association of CYP46 intron 2 polymorphism in Finnish Alzheimer’s disease samples and a global scale summary J Neurol Neurosurg Psychiatry 77 421-422
[23]  
Bjorkhem I(2002)Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer’s disease Neurosci Lett 328 9-12
[24]  
Lutjohann D(2002)Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer’s disease Mol Psychiatry 7 899-902
[25]  
Diczfalusy U(2004)APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer’s disease Neuroreport 15 95-98
[26]  
Papassotiropoulos A(2004)Genetic association of CYP46 and risk for Alzheimer’s disease Dement Geriatr Cogn Disord 18 257-260
[27]  
Streffer JR(2004)Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer’s disease Neurosci Lett 367 228-231
[28]  
Tsolaki M(2004)Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer’s disease Hum Genet 114 581-587
[29]  
Borroni B(2004)Exclusion of CYP46 and APOM as candidate genes for Alzheimer’s disease in a French population Neurosci Lett 363 139-143
[30]  
Archetti S(2004)Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer’s disease in Chinese Neurosci Lett 369 104-107